The pooled HR of these 4 studies showed that higher I/S ratio of CD68+ TAMs also indicated better OS in patients with NSCLC (HR = 0.28, 95% CI = 0.16 ~ 0.48, P < 0.00001; I2 = 55%, P = 0.08; Figure 5). Here, CD68 is linked to non-small cell lung carcinoma.